Brown, Lisle/Cummings’s AstraZeneca AZN Stock Holding History

Brown, Lisle/Cummings’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$110K	Sell	581 -36	-6%	-$6.77K	0.02%	297
2026 Q1	$122K	Buy	617 +156	+34%	+$30.1K	0.03%	268
2025 Q4	$84.8K	Sell	461 -75	-14%	-$13.2K	0.02%	299
2025 Q3	$82.2K	Hold	536	–	–	0.02%	297
2025 Q2	$74.9K	Hold	536	–	–	0.02%	298
2025 Q1	$78.7K	Buy	536 +43	+9%	+$6.22K	0.02%	293
2024 Q4	$64.6K	Buy	493 +39	+9%	+$5.46K	0.02%	302
2024 Q3	$70.7K	Hold	454	–	–	0.02%	291
2024 Q2	$70.8K	Hold	454	–	–	0.02%	280
2024 Q1	$61.5K	Hold	454	–	–	0.02%	275
2023 Q4	$61.2K	Hold	454	–	–	0.02%	271
2023 Q3	$61.5K	Hold	454	–	–	0.03%	253
2023 Q2	$65K	Hold	454	–	–	0.03%	259
2023 Q1	$63K	Buy	454 +79	+21%	+$10.6K	0.03%	257
2022 Q4	$50.8K	Buy	375 +16	+4%	+$2.01K	0.03%	264
2022 Q3	$39.4K	Hold	359	–	–	0.02%	274
2022 Q2	$47.4K	Buy	359 +15	+4%	+$1.97K	0.03%	265
2022 Q1	$45.6K	Buy	344 +44	+15%	+$5.28K	0.02%	272
2021 Q4	$35K	Buy	+300	New	+$35.3K	0.02%	301

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Brown, Lisle/Cummings's AZN Position: Q2 2026 in Review

Brown, Lisle/Cummings reduced its AstraZeneca (AZN) stake by 5.8% in Q2 2026, selling an estimated $6.77K and leaving 581 shares worth $110K. The position accounts for 0.02% of the portfolio, ranked #297.

Brown, Lisle/Cummings first reported a position in AZN in Q4 2021 and has held it in 19 quarters since. The position peaked at $122K in Q1 2026. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Brown, Lisle/Cummings held 581 shares of AstraZeneca worth $110K as of Q2 2026.
Brown, Lisle/Cummings sold 36 AstraZeneca shares in Q2 2026, an estimated $6.77K.
AstraZeneca made up 0.02% of Brown, Lisle/Cummings's portfolio in Q2 2026, its #297 holding.
Brown, Lisle/Cummings first reported a position in AstraZeneca in Q4 2021 and has held it in 19 quarters since.
Brown, Lisle/Cummings's AstraZeneca position peaked at $122K in Q1 2026.
1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q2 2026, filed 2 Sep 2026.